PBYI Q4 2024 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M-18.2% YoY

Gross Profit

$45M76.4% margin

Operating Income

$13M22.6% margin

Net Income

$19M32.7% margin

EPS (Diluted)

$0.39

QoQ Revenue Growth

-26.7%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$213M

Total Liabilities

$121M

Stockholders' Equity

$92M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$72M	-18.2%
Gross Profit	$45M	$48M	-5.6%
Operating Income	$13M	$15M	-9.7%
Net Income	$19M	$12M	+57.4%

Revenue Segments

Product

$95M92%

Royalty

$8M8%